SII CEO Adar Poonawalla mentioned on Saturday that its partnership for a Covid-19 vaccine with Novavax has proven wonderful efficacy outcomes.
“We’ve got utilized for beginning trials in India. Hope to launch Covocax by June 2021,” Poonawalla mentioned in a tweet.
The brand new vaccine shall be launched below the model identify of Covovax, which SII is manufacturing in partnership with Novovax. The Pune-based world vaccine large has sought permission from the DCGI to begin home trials of the brand new product.
The event comes shut on the heels of US-based biotechnology firm Novavax saying that its vaccine is 89.3 per cent efficient in stopping Covid-19 in a trial carried out within the UK.
The research assessed the efficacy of the vaccine — NVX-CoV2373 — throughout a interval with excessive transmission and with a brand new UK variant pressure of the virus rising and circulating extensively.
“NVX-CoV2373 has the potential to play an essential function in fixing this world public well being disaster. We stay up for persevering with to work with our companions, collaborators, investigators and regulators around the globe to make the vaccine out there as shortly as doable,” Stanley C. Erck, President and Chief Govt Officer, Novavax, mentioned in an announcement on Friday.
Final yr, Novavax had introduced its tie up with SII to supply 2 billion doses of Covid-19 vaccine.
